Organizations across the entire spectrum of the healthcare community are embracing translational medicine as the logical method to create better new medicines. Biotechnology companies themselves are often self-contained translational medicine organizations. This panel gathers several biotech companies who have successfully translated exciting bench science into promising drug candidates. Each of the participating companies in this session has a highly specialized biological knowledge. Based on their specialized scientific capabilities, the companies have undertaken development programs that have yielded CNS candidates addressing major unserved medical needs.

• Provide real world examples of the clicnial drug candidates arising from basic research through rigourously executed scientific process
• Demonstrate several examples of different CNS drug candidates that are the result of successful translational medicine efforts
• Educate on the variety of preclinical decision making nodes that make the tranlation from bench to clinic possible